Comparison · GLP-1
Compounded vs Branded GLP-1 · The Real Trade-Offs
Same molecule, different finished product, very different price. A physician-written guide to choosing safely between branded and compounded GLP-1 therapy.
The compounded vs branded GLP-1 question has become the single most common decision point in our practice. Branded Wegovy, Zepbound, Ozempic, and Mounjaro carry monthly cash prices in the four-figure range. Compounded semaglutide and compounded tirzepatide, prepared by state-licensed compounding pharmacies, deliver the same active molecule at a fraction of that cost. The trade-offs are real but they are often misrepresented on both sides of the conversation.
This page is the honest version. We explain what compounding actually is, how it is regulated, when it is appropriate, when it is not, and how to evaluate a compounding pharmacy. We also explain why the cost difference exists and what you give up · and do not give up · by choosing a compounded version.
Body Good Studio works with both branded and compounded medications and we recommend whichever is the better fit for the patient in front of us. The decision is rarely about which is medically superior · it is usually about access, cost, and which of the two roads is open to you right now.
Compounded vs branded GLP-1 · at a glance
| Branded (Wegovy, Zepbound, Ozempic, Mounjaro) | Compounded (semaglutide, tirzepatide) | |
|---|---|---|
| Active molecule | Semaglutide or tirzepatide | Semaglutide or tirzepatide |
| FDA-approved finished product | Yes | No (preparation by a state-licensed pharmacy) |
| Manufactured by | Novo Nordisk or Eli Lilly | 503A or 503B compounding pharmacy |
| Quality oversight | FDA cGMP at the manufacturer | USP standards plus state board of pharmacy |
| Typical monthly cost | 1,000 to 1,400 USD cash | 199 to 499 USD cash |
| Insurance coverage | Sometimes, with prior authorization | Rarely covered |
| Dose flexibility | Fixed pen doses on the label ladder | Custom dose increments possible |
| Available with B12 or other adjuncts | No (single-active product) | Sometimes, depending on pharmacy |
| Manufacturer savings card | Yes for commercial insurance | Not applicable |
What compounding actually is
A compounding pharmacy prepares a medication for an individual patient based on a prescription from a licensed clinician. Compounding has existed for as long as pharmacy itself · it is how medications were dispensed before mass manufacturing. Modern compounding pharmacies fall into two categories defined by federal law · 503A pharmacies prepare patient-specific prescriptions, and 503B outsourcing facilities prepare larger batches under FDA registration and inspection.
Both categories are legal. Both are regulated. Neither produces an FDA-approved finished product the way Novo Nordisk or Eli Lilly does · that distinction matters because FDA approval covers manufacturing process, stability data, sterility validation, and a long list of post-market surveillance requirements that simply are not part of compounding regulation. Compounding is regulated under the Federal Food, Drug, and Cosmetic Act sections 503A and 503B, plus state board of pharmacy oversight, and it is required to follow United States Pharmacopeia (USP) standards for sterile and non-sterile preparations.
Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredient (API) that the branded manufacturers use. The API is sourced from FDA-registered facilities and the pharmacy combines it with sterile water and a preservative to produce an injectable solution. The molecule does not change. What changes is who is responsible for the finished product and what level of validation has been done on that specific batch.
When compounded is appropriate
Compounded GLP-1 medications became widely available during the 2022 to 2024 shortage of branded semaglutide and tirzepatide. FDA shortage status allows 503A and 503B pharmacies to prepare versions of a drug that is otherwise commercially available. As of late 2024, both molecules came off the FDA shortage list, which narrowed but did not eliminate the legal grounds for compounding. Pharmacies can still compound when there is a documented clinical reason · for example, a patient who needs a non-standard dose, has an allergy to an inactive ingredient in the branded product, or who would otherwise be unable to access therapy due to cost.
Most patients who choose compounded GLP-1 do so because the branded option is not financially accessible. That is a legitimate clinical consideration · obesity is a chronic disease, and a medication a patient cannot afford to stay on long-term is unlikely to produce the long-term outcome they need. A compounded option that the patient can sustain for a year is often more clinically valuable than a branded option that has to be discontinued at month three.
Compounded is not appropriate for every patient. If your insurance covers branded therapy at a manageable copay, branded is the right choice · the FDA-approved finished product is the gold standard. If you have a complex medical history that benefits from the manufacturer-level quality data, branded is also the right choice. Compounded is a responsible alternative when the branded path is not open and when you are working with a clinician and a pharmacy that take quality seriously.
How to evaluate a compounding pharmacy
Not all compounding pharmacies are equal. The questions worth asking your provider before starting compounded GLP-1 are direct · is the pharmacy 503A or 503B, what state are they licensed in, do they use third-party USP testing for sterility and potency, where do they source their API, and what is their adverse event reporting protocol. Reputable pharmacies answer these questions in writing.
503B outsourcing facilities are inspected by the FDA, are required to follow current good manufacturing practice for outsourcing facilities, and report adverse events directly to the agency. 503A pharmacies are inspected by their state board of pharmacy and follow USP chapters 795, 797, and 800. Both are legitimate. 503B facilities tend to have more rigorous batch documentation and stability testing because they prepare for multiple patients per batch.
Body Good Studio works with a small set of vetted 503A and 503B pharmacies and we publish the pharmacy name on every prescription. Patients can verify the pharmacy independently with their state board of pharmacy. We never use a pharmacy that does not provide third-party testing on the active ingredient.
Cost · why the difference exists
Branded list prices reflect the cost of FDA approval, large-scale manufacturing, marketing, and the manufacturer's return on roughly a decade of clinical trial investment. Those costs are real and the resulting product is the gold standard. Insurance plans that cover branded therapy spread that cost across the risk pool · cash payers without insurance pay it directly.
Compounded prices reflect the cost of the API, sterile preparation, pharmacy overhead, and a much smaller marketing footprint. The molecule is the same, the regulatory framework is different, and the price difference is not a sign of inferior quality · it is a sign of a different cost structure.
For most patients without insurance coverage, the practical math looks like this · branded therapy at 1,200 USD per month is 14,400 USD per year. Compounded therapy at 299 USD per month is 3,588 USD per year. The compounded option is sustainable on a normal household budget. The branded option, without insurance, usually is not.
Our default recommendation
If your insurance covers branded Wegovy, Zepbound, Ozempic, or Mounjaro at a copay you can sustain, start branded. The FDA-approved finished product is the gold standard and you should use it when you can.
If your insurance does not cover branded therapy, or covers it at a copay that you would not be able to afford long-term, compounded semaglutide or compounded tirzepatide is a clinically reasonable alternative when prescribed by a physician and prepared by a vetted 503A or 503B pharmacy. The molecule is the same and the long-term outcome you can sustain matters more than the label on the bottle.
We make this recommendation explicitly during the intake quiz · brand-vs-compounded is presented as a choice the patient makes, with compounded as the preferred default for cash-pay patients because that is what produces the best long-term adherence and outcome in our practice.
Frequently asked questions
Is compounded GLP-1 legal?
Yes, when prescribed by a licensed clinician for an individual patient and prepared by a state-licensed 503A or 503B pharmacy. Compounding is regulated under federal and state law and has existed as long as pharmacy.
Is compounded semaglutide the same as Wegovy or Ozempic?
The active molecule is the same. The finished product is not FDA-approved · it is prepared by a compounding pharmacy under USP standards rather than by Novo Nordisk under FDA cGMP. The clinical effect is comparable when a vetted pharmacy is used.
Why is compounded so much cheaper?
Compounded versions skip the cost of FDA approval, large-scale brand manufacturing, and marketing. The active ingredient itself is a small portion of the branded price, so the same molecule costs much less when delivered through the compounding pathway.
Will my insurance cover compounded GLP-1?
Almost never. Compounded medications are typically not covered by commercial or government insurance plans. Patients pay cash. We use that cash price as the baseline when comparing total cost of therapy.
Find out which path is right for your situation
The two-minute quiz factors in your insurance, your weight goal, and your budget · then recommends branded or compounded therapy with the molecule that fits.
This page is educational and is not a substitute for medical advice. Compounded medications are not FDA-approved finished products. Eligibility, dosing, pharmacy choice, and pricing are determined after a clinical evaluation by a licensed physician.